Here, we describe the clinical trajectory and medical enigma of a patient with clear cell renal cell carcinoma treated with a combination of a programmed cell death protein 1 (PD-1)/CTLA4 inhibitor who had a sepsis-like presentation but was eventually diagnosed with HLH secondary to the ICI. The gene discussed is CTLA4; the disease is hemophagocytic syndrome.